Phase III Study Indicates Giredestrant Improves Outcomes for Advanced Breast Cancer

Results from the Phase III evERA Breast Cancer study, published in The New England Journal of Medicine, show that investigational giredestrant combined with everolimus significantly extended progression-free survival. This offers a potential new oral treatment option for patients with ER-positive locally advanced or metastatic breast cancer whose disease has progressed after CDK4/6 inhibitors and endocrine therapy.